Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ANIK
#2995
Anika Therapeutics Inc
14.360
0
+14.42%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+14.42%
Changement Mensuel
+55.50%
Evolution sur 6 mois
+41.62%
Changement Annuel
+41.62%
Clôture Précédente
12.550
0
Open
14.360
0
Bid
Ask
Low
14.360
0
High
14.360
0
Volume
44
Marchés
Actions des Marchés US
Soins de Santé
ANIK
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
14.33 M
14.47 M
14.63 M
14.85 M
14.18 M
—
Valuation ratios
Enterprise value
552.74 M
423.97 M
345.05 M
263.63 M
177.71 M
516.83 M
Price to earnings ratio
-26.78
127.96
-28.9
-4.02
-4.3
-14.88
Price to sales ratio
4.93
3.55
2.75
1.99
2.02
6.08
Price to cash flow ratio
49.27
62.44
97.36
185.74
44.85
137.02
Price to book ratio
2.36
1.83
1.5
1.56
1.57
2.37
Enterprise value to EBITDA ratio
-9.28
-41.24
-28.67
-3.36
-29.24
-41.01
Profitability ratios
Return on assets %
0.07
0.01
0.04
0.31
0.28
0.17
Return on equity %
0.09
0.01
0.05
0.39
0.37
0.22
Return on invested capital %
50.18
1.3
28.3
200.62
-20.05
49.65
Gross margin %
52.91
56.12
59.89
61.85
63.38
218.99
Operating margin %
21.71
1.77
12.42
52.58
4.25
45.11
EBITDA margin %
-45.63
-6.96
-7.7
-47.08
-5.07
-51.21
Net margin %
18.38
2.8
9.51
49.6
47.02
112.51
Liquidity ratios
Quick ratio
3.56
4.45
4.65
3.76
3.85
17.98
Current ratio
4.81
5.66
6.07
5.26
4.88
22.1
Inventory turnover
1.8
1.58
1.65
1.48
1.25
2.39
Asset turnover
0.37
0.41
0.45
0.54
0.51
0.57
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.92
0.57
0.3
0.12
0.37
0.56
EBIT per share
-5.15
-1.69
-1.83
-6.32
-0.8
-1.42
EBITDA per share
-4.19
-0.7
-0.83
-5.35
-0.41
-0.99
Total debt per share
—
—
—
—
—
—
Cash per share
6.91
6.45
8.31
7.43
5.38
21.53
Net current asset value per share
12.47
11.52
11.64
11.14
7.72
28.78
Tangible book value per share
12.15
13.46
13.98
13.65
9.81
38.52
Working capital per share
9.88
9.48
9.73
9.02
6.14
23.51
Book value per share
19.15
19.62
19.61
14.48
10.46
41.19
Nouvelles
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika T4 2025 : poussée commerciale compense le recul OEM
Anika Q4 2025 slides: commercial surge offsets OEM decline
Le BPA de Anika a dépassé les attentes de 0,45$, le CA a surpassé les prévisions
Anika earnings beat by $0.45, revenue topped estimates
Lumicell appoints Cheryl Blanchard to board of directors
Anika Therapeutics nomme Stephen Griffin comme nouveau PDG
Anika Therapeutics names Stephen Griffin as new CEO
Diapositives du T3 2025 d’Anika : La croissance commerciale compense le déclin OEM
Anika Q3 2025 slides: Commercial growth offsets OEM decline
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika earnings beat by $0.22, revenue was in line with estimates